Lumos Diagnostics Holdings Ltd Cash Flow Conversion Efficiency
Lumos Diagnostics Holdings Ltd cash flow conversion efficiency. Based on the latest financial reports, Lumos Diagnostics Holdings Ltd (LDX) has a cash flow conversion efficiency ratio of 0.149x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$778.03K ≈ $550.51K USD) by net assets (AU$5.24 Million ≈ $3.70 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Lumos Diagnostics Holdings Ltd (2017–2024)
Cash flow conversion efficiency of Lumos Diagnostics Holdings Ltd from 2017 to 2024. This chart illustrates how Lumos Diagnostics Holdings Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View LDX share price today for real-time trading data and today's change.
Lumos Diagnostics Holdings Ltd Cash Flow Conversion Ratio Explained
Lumos Diagnostics Holdings Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Lumos Diagnostics Holdings Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Lumos Diagnostics Holdings Ltd ranked by their cash flow conversion efficiency. Also see LDX market cap overview for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Swiss Properties Invest A/S
CO:SWISS
|
0.011x |
|
Ji-Haw Industrial Co Ltd
TW:3011
|
-0.063x |
|
UNIQUE
KLSE:0257
|
0.082x |
|
Uniform Industrial Corp
TW:2482
|
0.006x |
|
LightInTheBox Holding Co Ltd ARD
NYSE:LITB
|
-2.224x |
|
PanGen Biotech Inc
KQ:222110
|
-0.122x |
|
Goa Carbon Limited
NSE:GOACARBON
|
-0.176x |
|
Grandstand Limited
NASDAQ:GRSD
|
0.017x |
Annual Cash Flow Conversion Efficiency for Lumos Diagnostics Holdings Ltd (2017–2024)
The table below shows the annual cash flow conversion efficiency of Lumos Diagnostics Holdings Ltd from 2017 to 2024. Review Lumos Diagnostics Holdings Ltd (LDX) FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | AU$6.16 Million ≈ $4.36 Million |
AU$-9.33 Million ≈ $-6.60 Million |
-1.516x | -1239.24% |
| 2023-12-31 | AU$7.11 Million ≈ $5.03 Million |
AU$946.00K ≈ $669.36K |
0.133x | +113.11% |
| 2022-12-31 | AU$9.50 Million ≈ $6.72 Million |
AU$-9.64 Million ≈ $-6.82 Million |
-1.015x | -0.62% |
| 2021-12-31 | AU$17.89 Million ≈ $12.65 Million |
AU$-18.04 Million ≈ $-12.76 Million |
-1.008x | -439.75% |
| 2020-12-31 | AU$58.28 Million ≈ $41.24 Million |
AU$-10.89 Million ≈ $-7.70 Million |
-0.187x | -10.16% |
| 2019-12-31 | AU$22.16 Million ≈ $15.68 Million |
AU$-3.76 Million ≈ $-2.66 Million |
-0.170x | +34.83% |
| 2018-12-31 | AU$11.66 Million ≈ $8.25 Million |
AU$-3.03 Million ≈ $-2.15 Million |
-0.260x | -168.72% |
| 2017-12-31 | AU$2.98 Million ≈ $2.11 Million |
AU$-288.67K ≈ $-204.25K |
-0.097x | -- |
About Lumos Diagnostics Holdings Ltd
Lumos Diagnostics Holdings Limited develops, manufactures, and commercializes point-of-care diagnostic products for diagnosis and management of infectious diseases in the United States. The company's products include FebriDx, a point-of-care diagnostic test for detecting and differentiating viral and bacterial respiratory infections; and ViraDx, a three-in-one point-of-care test for influenza A, … Read more